Literature DB >> 15138702

[Laser microdissection and molecular typing of dysplastic cells from Pap smears: a new approach to early detection of cervical cancer].

C Eder1, R S K Chaganti, V V V S Murty, K-R Greskötter, M Giesing.   

Abstract

The Papanicolaou smear (Pap) is a worldwide screening tool for early detection of cervical cancer and its precursor lesions. The transition from dysplasia to cancer is a highly complex genetic process and cannot be predicted based solely on cell morphology. Molecular characterization of precursor lesions could yield a better definition of lesions at high risk for progression. We developed an analytical concept comprising not only morphological characterization but also molecular analysis with multiple parameters of dysplastic cells from cervical smears. We isolated dysplastic cells from 52 fixed Pap-stained smears of various grades by laser microdissection and analyzed them for genetic lesions typical for cervical carcinoma. The loss of heterozygosity (LOH) as published for cervical carcinoma tissue was detected. Markers for early stages showed a LOH in 43% and 22%, and those for late stages in 26% of the cases. Combining morphological characterization with molecular analysis by multiple molecular markers could open up new opportunities for early detection of cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15138702     DOI: 10.1007/s00292-003-0663-4

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  19 in total

1.  Distinct cytogenetic alterations in squamous intraepithelial lesions of the cervix revealed by laser-assisted microdissection and comparative genomic hybridization.

Authors:  M Aubele; H Zitzelsberger; U Schenck; A Walch; H Höfler; M Werner
Journal:  Cancer       Date:  1998-12-25       Impact factor: 6.860

2.  Laser capture microdissection.

Authors:  M R Emmert-Buck; R F Bonner; P D Smith; R F Chuaqui; Z Zhuang; S R Goldstein; R A Weiss; L A Liotta
Journal:  Science       Date:  1996-11-08       Impact factor: 47.728

3.  Genetic deletion and human papillomavirus infection in cervical cancer: loss of heterozygosity sites at 3p and 5p are important genetic events.

Authors:  A B Mitra
Journal:  Int J Cancer       Date:  1999-07-30       Impact factor: 7.396

4.  Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study.

Authors:  J S Park; S M Dong; H S Kim; J Y Lee; S J Um; I S Park; S J Kim; S E Namkoong
Journal:  Cancer Lett       Date:  1999-02-08       Impact factor: 8.679

5.  Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix.

Authors:  A M Kersemaekers; M J van de Vijver; G G Kenter; G J Fleuren
Journal:  Genes Chromosomes Cancer       Date:  1999-12       Impact factor: 5.006

6.  Genomic deletion and p53 inactivation in cervical carcinoma.

Authors:  W H Ku; I L Liu; M S Yen; C C Chang Chien; C T Yue; Y Y Ma; S F Chang; H T Ng; C W Wu; C Y Shen
Journal:  Int J Cancer       Date:  1997-07-17       Impact factor: 7.396

7.  State of mutational alterations of p53 and retinoblastoma susceptibility genes in papillomavirus-negative small cell cervical carcinomas.

Authors:  C C Pao; S M Kao; J H Chen; G C Tang; P Y Chang; T T Tan
Journal:  J Surg Oncol       Date:  1994-10       Impact factor: 3.454

8.  Genomic alterations in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status.

Authors:  M R Mullokandov; N G Kholodilov; N B Atkin; R D Burk; A B Johnson; H P Klinger
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

9.  Multiple mutation analyses in single tumor cells with improved whole genome amplification.

Authors:  W Dietmaier; A Hartmann; S Wallinger; E Heinmöller; T Kerner; E Endl; K W Jauch; F Hofstädter; J Rüschoff
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

Review 10.  The molecular genetics of cervical carcinoma.

Authors:  P A Lazo
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.